ICPT News and Press, Intercept Pharmaceuticals Inc. From 08/18/22

MORRISTOWN, N.J., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the management team of I...

U.S. biotech Intercept Pharmaceuticals ( NASDAQ: ICPT ) and India-based Dr. Reddy's Laboratories ( RDY ) have reached an agreement to settle a lawsuit over Dr. Reddy's plans to market a generic version of Intercept's ( ICPT ) liver disease therapy Ocaliva. The farnes...

Intercept Pharmaceuticals has an important binary event coming up: the FDA’s decision regarding their NDA for Ocaliva in treating NASH. Information included in its most recent earnings report does little to inspire hope that this next decision will be any different from the las...

Since the mid-June lows, highly shorted names have again been outperforming. On a relative basis, the most heavily shorted stocks have been outperforming the Russell 3,000 in that time. This has resulted in the relative strength line to break out of the downtrend that has been in ...

Intercept Pharma ( NASDAQ: ICPT ) is up 13% after reporting growth in Q2 2022 revenue compared to the prior-year period and indicating it would resubmit an NDA for Ocaliva for non-alcoholic steatohepatitis ( NASH ). Intercept ( ICPT ) said following a meeting w...

Intercept Pharmaceuticals, Inc. (ICPT) Q2 2022 Results Conference Call August 02, 2022 08:30 AM ET Company Participants Nareg Sagherian - ED, IR Jerry Durso - President and CEO Linda Richardson - Chief Commercial Officer Dr. Michelle Berrey - President of Res...

Intercept Pharma press release ( NASDAQ: ICPT ): Q2 EPS of -$0.68 may not be comparable to consensus of $1.33. Revenue of $71.76M (+5.3% Y/Y). Company reissues 2022 financial guidance to reflect impact of sale of international business: Ocaliva non-GAAP adjusted net sa...

Worldwide Ocaliva® non-GAAP adjusted net sales in PBC of $100.4 million; U.S. net sales of $71.8 million representing 5% growth over the prior year quarter Company reissues 2022 financial guidance to reflect impact of sale of international business: Ocaliva non-GAAP adjuste...

Intercept Pharma ( NASDAQ: ICPT ) is scheduled to announce Q2 earnings results on Wednesday, August 3rd, before market open. The consensus EPS Estimate is $1.33 (+503.0% Y/Y) and the consensus Revenue Estimate is $123.49M (+27.9% Y/Y). Over the last 1 year, ICPT has ...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings for companies due to report...